The antiapoptotic BCL-2 protein MCL-1, which opposes mitochondrial outer membrane permeabilization, was shown to have a crucial role in the survival of hematopoietic cells. We have previously shown that, upon loss of phosphatidylinositol 3-kinase signaling, S159 of MCL-1 is phosphorylated by glycogen synthase kinase-3 (GSK-3), earmarking MCL-1 for enhanced ubiquitylation and degradation. In this study, we introduced MCL-1 wt or the phosphorylation-deficient mutant MCL-1 S159A in mouse BM cells, followed by adoptive transfer to recipient mice. Mice expressing MCL-1 S159A exhibited significantly elevated white blood cell and lymphocyte counts, whereas no effect was observed on the distribution of T and B lymphocyte subsets or the numbers of monocytes, red blood cells or platelets. Expression of MCL-1 S159A in Em-Myc transgenic bone marrow significantly accelerated the onset of disease, and these mice displayed increased spleen weights compared with Em-Myc/MCL-1 wt mice. Our data demonstrate that the absence of MCL-1 S159 phosphorylation provides a survival advantage for hematopoietic cells in vivo and facilitates oncogenesis.
INTRODUCTION
Proteins of the BCL-2 family control the permeabilization of the mitochondrial outer membrane, which is a key regulatory mechanism for the induction of apoptosis. The BCL-2 protein MCL-1, which prevents mitochondrial outer membrane permeabilization, was shown to be essential for the survival of T-and B-cells, as well as of neutrophils and hematopoietic stem cells. [1] [2] [3] [4] We have previously demonstrated that the cytokine interleukin-3 (IL-3) maintains the survival of pro-B-cell lines by stabilization of MCL-1. IL-3 induces the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which negatively regulates glycogen synthase kinase-3 (GSK-3) through inhibitory phosphorylation. 5 Conversely, upon loss of PI3K signaling, we found that GSK-3 phosphorylates MCL-1 on S159, earmarking MCL-1 for enhanced ubiquitylation and degradation. Thus, inhibition of GSK-3 or replacement of S159 by alanine resulted in MCL-1 stabilization and prevention from apoptosis. 6 Although similar findings were reported by a number of subsequent studies by others, [7] [8] [9] [10] the in vivo role of this post-translational modification of MCL- 1 has not yet been addressed.
RESULTS AND DISCUSSION
In this study, we investigated the relevance of MCL-1 S159 phosphorylation in vivo. We used a murine bone marrow (BM) transplantation strategy retrovirally introducing the human version of MCL-1 or the GSK-3 phosphorylation-deficient mutant MCL-1 S159A , followed by adoptive BM transfer of infected donor cells to lethally irradiated recipient mice. Equal transduction levels by pMIG control, wild-type or mutant MCL-1 encoding retroviruses were crucial for our experiments, and were assured by (i) testing virus supernatants for equal multiplicity of infection, (ii) analyzing infected donor BM for equal levels of green fluorescent protein (GFP) and thus inferred MCL-1 or MCL-1 S159A mRNA expression, by flow cytometry (Figures 1a and b) and (iii) quantitative reverse transcription-polymerase chain reaction analysis (Supplementary Figure S1A) .
Four weeks after transplantation, the mice that had received BM infected with phosphorylation-deficient MCL-1 S159A BM (n ¼ 30) exhibited a significantly elevated white blood cell (WBC) count (9.07 Â 10 3 /ml) compared with mice expressing wild-type MCL-1 (6.95 Â 10 3 /ml, n ¼ 29, P ¼ 0.0014), whereas mice expressing control vector pMIG (n ¼ 29) had a significantly lower average WBC count (5.37 Â 10 3 /ml) ( Figure 1c) . Likewise, lymphocyte (P ¼ 0.0015; Figure 1d ) and neutrophil granulocyte numbers (Supplementary Figure S1B) were highest in mice, which had received BM infected with MCL-1 S159A , whereas the numbers of monocytes, platelets and red blood cells were independent of expression of MCL-1 wt or MCL-1 S159A (Supplementary Figures S1C-E ). This effect of MCL-1 phosphorylation on lymphocyte and neutrophil granulocytes numbers may reflect the general requirement of MCL-1 for the survival of these cell types. [1] [2] [3] Six weeks after adoptive transfer, BM, thymocytes, splenocytes and lymph node lymphocytes were examined. Importantly, the mean fluorescence intensity of GFP in BM cells expressing MCL-1-IRES-GFP or MCL-1 S159A -IRES-GFP was equal, indicating that the 1 mRNA levels for MCL-1 wt and MCL-1 S159A were similar (Figure 1e ), and thus the effects of MCL-1 S159A expression on cell numbers were not attributable to different vector expression levels, but correlated with the mutation status of MCL-1. We did not observe an effect of MCL-1 or MCL-1 S159A expression on proliferation in vivo or in cell lines, ruling out that this was the cause for the difference in cell numbers (Supplementary Figure S1F and data not shown). (Figure 1g ). The distribution of the B-cell subpopulations in the BM was independent of the expression of MCL-1 wt or MCL-1 S159A (Supplementary Figure S2A) . In the spleen and lymph nodes, the distribution of T and B cells was not influenced by the expression of MCL-1 wt or MCL-1 S159A
(Supplementary Figures S2B and C) , and the distribution of splenic B cells at maturation stages T1, T2 and FO also remained unchanged (Supplementary Figure S2D) . Likewise, the percentage of CD4 þ and CD8 þ cells among GFP þ thymocytes, splenocytes and lymph node lymphocytes was similar in mice with BM expressing pMIG control, MCL-1 wt or MCL-1 S159A ( Supplementary  Figures S2E-G) . In sum, this demonstrates that the expression of MCL-1 or MCL-1 S159A does not affect the differentiation potential of one or the other leukocyte subset in vivo, but leads to a comparable expansion of all cell types expressing the transgene. We analyzed the protein expression levels of MCL-1 in splenocytes derived from mice, which had received BM-expressing MCL-1 or MCL-1 S159A . Consistent with previous results, showing that MCL-1S159 phosphorylation decreases MCL-1 stability, [6] [7] [8] splenocytes expressing the phosphorylation-deficient mutant exhibited significantly elevated protein levels (Figure 1h and Supplementary Figure S2H) . Analysis of mRNA from MCL-1 or MCL-1 S159A BM cells demonstrated that this was not due to different mRNA expression levels (Supplementary Figure S1A) .
Antiapoptotic BCL-2 family members such as BCL-2 and, as shown more recently, MCL-1 strongly accelerate the development of c-Myc-induced lymphoma. [11] [12] [13] To investigate whether phosphorylation-deficient MCL-1 promotes accelerated lymphoma development by cooperating with oncogenic Myc more potently than wild-type MCL-1, we infected pooled BM cells from young Em-Myc transgene-positive donor mice (age o5 weeks) with control vector pMIG, MCL-1 wt or MCL-1 S159A , followed by flow cytometry analysis for equal expression of GFP, and thus pMIG, and MCL-1 wt -or MCL-1 S159A -encoding vectors, and subsequent transplantation into irradiated recipient mice. Eµ-myc/ MCL-1 S159A Figure 2 . S159 phosphorylation-deficient MCL1 accelerates lymphoma. (a) Em-Myc transgenic mice have been described. 20 Em-Myc BM cells were infected with retrovirus supernatants, followed by adoptive transfer to irradiated recipient mice. Kaplan-Meier curve of disease-free survival as defined (WBC 422 Â 10 : Lymphoblasts (arrows) infiltrate and destroy the architecture of the spleen and the BM where hematopoiesis is completely replaced by the lymphoid blasts.
We used elevated WBC count in the peripheral blood as an early indicator for the onset of leukemia, as palpable tumors occurred only at later stages (6-8 weeks after BM transfer).
Four weeks after BM transfer, premalignant mice, which had received Em-Myc MCL-1 S159A BM (as compared with Em-Myc MCL-1 wt mice) exhibited a trend to elevated WBC counts (Supplementary Figure S3A) , lymphocyte and neutrophil granulocyte counts (Supplementary Figures S3B and C) . No difference was observed for numbers of red blood cells and platelets ( Supplementary Figures S3D and E) . As observed before with non-malignant BM, Em-Myc cells expressing MCL-1 S159A competed out against uninfected cells more efficiently than did Em-Myc cells expressing MCL-1 wt (Supplementary Figure S3F) . As shown by Kaplan-Meier plot and statistical comparison by log-rank test, Em-Myc/MCL-1 S159A -expressing mice exhibited a significantly earlier onset of leukemia than Em-Myc/MCL-1 wtexpressing animals (P ¼ 0.0424), whereas only one control (vector-expressing) Em-Myc/pMIG mouse showed significantly elevated WBC in the period of time analyzed (Figure 2a) . Consistently, Em-Myc/MCL-1 S159A mice, in comparison to Em-Myc/ MCL-1 wt -expressing mice, exhibited elevated spleen weight when terminated after exhibiting palpable tumors (Figure 2b) .
All of the MCL-1/Em-Myc-and Em-Myc/MCL-1 S159A -expressing mice developed malignant lymphoma with massive B-cell infiltration into the spleen and BM (Figure 2c ). Interestingly, in contrast to recent findings of B220
þ IgM þ lymphoma with vav-MCL-1/Em-Myc double transgenic animals, 13 these tumors were, with the exception of a single MCL-1/Em-Myc animal, all B220
þ IgM À pre-B-cell lymphoma. High PI3K signaling has been observed in many tumors, including lymphoblastic leukemia 14, 15 and has recently been shown to cooperate with c-MYC in Burkitt's lymphomagenesis. 16 Likewise, the frequent amplification of MCL-1 in a variety of tumors 17 and the protection from Myc-induced leukemia by the absence of a single MCL-1 allele 18 underscores the dosagedependent role of MCL-1 protein levels for tumor cell survival.
Here we show, in an animal model, that the absence of MCL-1 S159 phosphorylation, usually achieved by cytokine-dependent, AKT-mediated GSK-3 inactivation, represents a mechanism by which constitutive PI3K signaling contributes to lymphadenopathy fostering malignancy, and possibly therapy resistance. As MCL-1 represents the main barrier for the response to the BH3 mimetic ABT-737, 19 the modulation of MCL-1 function by interfering with its post-translational modifications has gained particular attention. Our data suggest that drugs interfering with PI3K signaling may well cooperate with ABT-263 in vivo and that targeting kinase signaling pathways, stabilizing MCL-1, which are activated in cancer cells, may be less detrimental to healthy cells as compared with targeting MCL-1 directly.
